GlaxoSmithKline splashes out $1.4 billion on Aiolos Bio, Inc

Another day, another biopharmaucetical takeover by a major pharmaceutical company.

This time it's the turn of FTSE 100-listed GlaxoSmithKline, which is paying $1.4 billion for Aiolos Bio, Inc, a clinical-stage biopharmaceutical company developing treatments for respiratory and inflammatory conditions.

Below is the link to this morning if you would like to read all the details of the transaction:..


Register for free to see rest of this article and all public articles from Betaville

Login / Register
Date: Tuesday, 9 January 2024, 7:49 am

[Disclaimer - the information on Betaville does not consitute any form of investment recommendation and is not intended to be relied upon by readers in making, or refraining from, any investment decisions].

Login to join the conversation